287 related articles for article (PubMed ID: 21704169)
61. Bacteria as DNA vaccine carriers for genetic immunization.
Schoen C; Stritzker J; Goebel W; Pilgrim S
Int J Med Microbiol; 2004 Oct; 294(5):319-35. PubMed ID: 15532991
[TBL] [Abstract][Full Text] [Related]
62. A Lactococcus lactis expression vector set with multiple affinity tags to facilitate isolation and direct labeling of heterologous secreted proteins.
Romero Pastrana F; Neef J; van Dijl JM; Buist G
Appl Microbiol Biotechnol; 2017 Nov; 101(22):8139-8149. PubMed ID: 28971274
[TBL] [Abstract][Full Text] [Related]
63. Another Breaker of the Wall: the Biological Function of the Usp45 Protein of Lactococcus lactis.
Hernandez-Valdes JA; Huang C; Kok J; Kuipers OP
Appl Environ Microbiol; 2020 Aug; 86(16):. PubMed ID: 32532874
[No Abstract] [Full Text] [Related]
64. A review on Lactococcus lactis: from food to factory.
Song AA; In LLA; Lim SHE; Rahim RA
Microb Cell Fact; 2017 Apr; 16(1):55. PubMed ID: 28376880
[TBL] [Abstract][Full Text] [Related]
65. Production of Fibronectin Binding Protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo.
Pontes D; Innocentin S; Del Carmen S; Almeida JF; Leblanc JG; de Moreno de Leblanc A; Blugeon S; Cherbuy C; Lefèvre F; Azevedo V; Miyoshi A; Langella P; Chatel JM
PLoS One; 2012; 7(9):e44892. PubMed ID: 23028664
[TBL] [Abstract][Full Text] [Related]
66. Heterologous protein expression by Lactococcus lactis.
Villatoro-Hernández J; Kuipers OP; Saucedo-Cárdenas O; Montes-de-Oca-Luna R
Methods Mol Biol; 2012; 824():155-65. PubMed ID: 22160898
[TBL] [Abstract][Full Text] [Related]
67. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.
Wang M; Gao Z; Zhang Y; Pan L
Appl Microbiol Biotechnol; 2016 Jul; 100(13):5691-701. PubMed ID: 27154346
[TBL] [Abstract][Full Text] [Related]
68. Construction of a new shuttle vector for DNA delivery into mammalian cells using non-invasive Lactococcus lactis.
Yagnik B; Padh H; Desai P
Microbes Infect; 2016 Apr; 18(4):237-44. PubMed ID: 26655884
[TBL] [Abstract][Full Text] [Related]
69. Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides.
Plavec TV; Berlec A
Appl Microbiol Biotechnol; 2019 Mar; 103(5):2053-2066. PubMed ID: 30656391
[TBL] [Abstract][Full Text] [Related]
70. Novel Strategies for Efficient Production and Delivery of Live Biotherapeutics and Biotechnological Uses of
Tavares LM; de Jesus LCL; da Silva TF; Barroso FAL; Batista VL; Coelho-Rocha ND; Azevedo V; Drumond MM; Mancha-Agresti P
Front Bioeng Biotechnol; 2020; 8():517166. PubMed ID: 33251190
[TBL] [Abstract][Full Text] [Related]
71. Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease.
Yuvaraj S; Al-Lahham S; Marreddy RK; Dijkstra G; Wolken WA; Lolkema JS; Helfrich W; Johansen FE; Peppelenbosch MP; Bos NA
Mol Nutr Food Res; 2008 Aug; 52(8):913-20. PubMed ID: 18504703
[TBL] [Abstract][Full Text] [Related]
72. Versatile vector suite for the extracytoplasmic production and purification of heterologous His-tagged proteins in Lactococcus lactis.
Neef J; Milder FJ; Koedijk DG; Klaassens M; Heezius EC; van Strijp JA; Otto A; Becher D; van Dijl JM; Buist G
Appl Microbiol Biotechnol; 2015 Nov; 99(21):9037-48. PubMed ID: 26160391
[TBL] [Abstract][Full Text] [Related]
73. Effect of Secretion Efficiency of Mutant KRAS Neoantigen by
Alias NAR; Hoo WPY; Siak PY; Othman SS; Mohammed Alitheen NB; In LLA; Abdul Rahim R; Song AA
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240273
[TBL] [Abstract][Full Text] [Related]
74. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.
Bermúdez-Humarán LG; Kharrat P; Chatel JM; Langella P
Microb Cell Fact; 2011 Aug; 10 Suppl 1(Suppl 1):S4. PubMed ID: 21995317
[TBL] [Abstract][Full Text] [Related]
75. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update.
LeBlanc JG; Aubry C; Cortes-Perez NG; de Moreno de LeBlanc A; Vergnolle N; Langella P; Azevedo V; Chatel JM; Miyoshi A; Bermúdez-Humarán LG
FEMS Microbiol Lett; 2013 Jul; 344(1):1-9. PubMed ID: 23600579
[TBL] [Abstract][Full Text] [Related]
76. Engineered commensal bacteria as delivery systems of anti-infective mucosal protectants.
Magliani W; Conti S; Frazzi R; Pozzi G; Oggioni M; Polonelli L
Biotechnol Genet Eng Rev; 2002; 19():139-56. PubMed ID: 12520876
[No Abstract] [Full Text] [Related]
77. Lactococcus lactis-based vaccines from laboratory bench to human use: an overview.
Bahey-El-Din M
Vaccine; 2012 Jan; 30(4):685-90. PubMed ID: 22154771
[TBL] [Abstract][Full Text] [Related]
78. Genetic immunization: bacteria as DNA vaccine delivery vehicles.
Becker PD; Noerder M; Guzmán CA
Hum Vaccin; 2008; 4(3):189-202. PubMed ID: 20686358
[TBL] [Abstract][Full Text] [Related]
79. Lactic acid bacteria as live vaccines.
Mercenier A; Müller-Alouf H; Grangette C
Curr Issues Mol Biol; 2000 Jan; 2(1):17-25. PubMed ID: 11464916
[TBL] [Abstract][Full Text] [Related]
80. Main Features of DNA-Based Vectors for Use in Lactic Acid Bacteria and Update Protocols.
Coelho-Rocha ND; Barroso FAL; Tavares LM; Dos Santos ESS; Azevedo V; Drumond MM; Mancha-Agresti P
Methods Mol Biol; 2021; 2197():285-304. PubMed ID: 32827144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
